dc.contributor.author |
Khoriaty R. |
dc.contributor.author |
Taher A. |
dc.contributor.author |
Inati A. |
dc.contributor.author |
Lee C. |
dc.contributor.editor |
|
dc.date |
Oct-2005 |
dc.date.accessioned |
2017-10-05T15:40:14Z |
dc.date.available |
2017-10-05T15:40:14Z |
dc.date.issued |
2005 |
dc.identifier |
10.1111/j.1365-2257.2005.00716.x |
dc.identifier.isbn |
|
dc.identifier.issn |
01419854 |
dc.identifier.uri |
http://hdl.handle.net/10938/17329 |
dc.description.abstract |
Patients with severe haemophilia can be treated for bleeding either prophylactically or on demand. Each treatment modality has advantages and disadvantages from both a medical and economic point of view. This study aims to find which modality requires more units of clotting factors per body weight per year and to compare the number of bleeds between the two. The study sample consisted of 133 patients with severe haemophilia A and B treated in the Katharine Dormandy Haemophilia Centre at the Royal Free Hampstead NHS Trust in London. The average number of clotting factors used per body weight per year was 2181.7 units for prophylaxis vs. 711 units for on demand treatment (P = 0.000). Although more units used means more money spent, and although prophylaxis has additional complications, namely venipunctures and increased risk of viral contamination, other criteria must be considered including the total number of bleeds and health-related quality of life. The total number of bleeds per year was significantly (P = 0.021) less for prophylactically (7.4) vs. on-demand treated patients (11.4). This suggests that prophylaxis reduces the risk of arthropathies, the number of future hospital visits and orthopaedic surgeries, and is thus the optimal modality of treatment for patients with severe haemophilia. © 2005 Blackwell Publishing Ltd. |
dc.format.extent |
|
dc.format.extent |
Pages: (320-323) |
dc.language |
English |
dc.publisher |
OXFORD |
dc.relation.ispartof |
Publication Name: Clinical and Laboratory Haematology; Publication Year: 2005; Volume: 27; no. 5; Pages: (320-323); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
A comparison between prophylaxis and on demand treatment for severe haemophilia |
dc.type |
Article |
dc.contributor.affiliation |
Khoriaty, R., American University of Beirut, Beirut, Lebanon, American University of Beirut, PO Box: 11-0236-2182, Riad El-Solh-Beirut 1107 2020, Lebanon |
dc.contributor.affiliation |
Taher, A., American University of Beirut, Beirut, Lebanon |
dc.contributor.affiliation |
Inati, A., American University of Beirut, Beirut, Lebanon, Nini Hospital, Tripoli, Lebanon |
dc.contributor.affiliation |
Lee, C., American University of Beirut, Beirut, Lebanon, Katharine Dormandy Haemophilia Centre, Royal Free Hampstead NHS Trust, London, United Kingdom |
dc.contributor.authorAddress |
Khoriaty, R.; American University of Beirut, PO Box: 11-0236-2182, Riad El-Solh-Beirut 1107 2020, Lebanon; email: rnk04@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; |
dc.contributor.authorDepartment |
Internal Medicine |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
rkhoriaty@hotmail.com |
dc.contributor.faculty |
Faculty of Medicine |
dc.contributor.authorInitials |
Khoriaty, R |
dc.contributor.authorInitials |
Taher, A |
dc.contributor.authorInitials |
Inati, A |
dc.contributor.authorInitials |
Lee, C |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Khoriaty, R (reprint author), Am Univ Beirut, POB 11-0236-2182,Riad Elsolh 1107, Beirut 2020, Lebanon. |
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut Medical Center |
dc.description.cited |
Aznar JA, 2000, HAEMOPHILIA, V6, P170, DOI 10.1046-j.1365-2516.2000.00397.x; Berntorp E, 1995, B WORLD HEALTH ORGAN, V73, P691; DIMITRIOS P, 2002, EMEDICINE J, V3; Fischer K, 2002, BLOOD, V99, P2337, DOI 10.1182-blood.V99.7.2337; GIRVAN DP, 1994, J PEDIATR SURG, V29, P1220, DOI 10.1016-0022-3468(94)90806-0; Medeiros D, 1998, HAEMOPHILIA, V4, P10; MICHELSON AD, 1995, CHEST, V108, pS506, DOI 10.1378-chest.108.4_Supplement.506S; Miners AH, 1999, HAEMOPHILIA, V5, P378; Miners AH, 2000, J INTERN MED, V247, P493, DOI 10.1046-j.1365-2796.2000.00633.x; Molho P, 2000, HAEMOPHILIA, V6, P23; NILSSON IM, 1976, ACTA PAEDIATR SCAND, V65, P129, DOI 10.1111-j.1651-2227.1976.tb16525.x; PETTERSSON H, 1981, ACTA PAEDIATR SCAND, V70, P565, DOI 10.1111-j.1651-2227.1981.tb05741.x; Rodriguez-Merchan EC, 1999, HAEMOPHILIA, V5, P53, DOI 10.1046-j.1365-2516.1999.0050s1053.x; Smith PS, 1996, J PEDIATR, V129, P424, DOI 10.1016-S0022-3476(96)70076-8; STEVENS M, 1994, TRANSFUSION, V34, pA133; Szucs TD, 1996, HAEMOPHILIA, V2, P211, DOI 10.1111-j.1365-2516.1996.tb00139.x; WESENBERG F, 1993, PEDIATR HEMAT ONCOL, V10, P233, DOI 10.3109-08880019309029489; ZAPPA SC, 1994, ARCH PEDIAT ADOL MED, V148, P327 |
dc.description.citedCount |
11 |
dc.description.citedTotWOSCount |
10 |
dc.description.citedWOSCount |
9 |
dc.format.extentCount |
4 |
dc.identifier.articleNo |
|
dc.identifier.coden |
CLHAD |
dc.identifier.pubmedID |
16178913 |
dc.identifier.scopusID |
26044455717 |
dc.identifier.url |
|
dc.publisher.address |
9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Clin. Lab. Haematol. |
dc.relation.ispartOfIssue |
5 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Clinical and Laboratory Haematology |
dc.relation.ispartofPubTitleAbbr |
Clin. Lab. Haematol. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
27 |
dc.source.ID |
WOS:000232047000008 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
Bleeding |
dc.subject.otherAuthKeyword |
Coagulation factors |
dc.subject.otherAuthKeyword |
Haemophilia |
dc.subject.otherAuthKeyword |
On demand |
dc.subject.otherAuthKeyword |
Prophylaxis |
dc.subject.otherChemCAS |
recombinant blood clotting factor 9, 177403-26-8, 178900-90-8 |
dc.subject.otherChemCAS |
Blood Coagulation Factors |
dc.subject.otherIndex |
blood clotting factor |
dc.subject.otherIndex |
recombinant blood clotting factor 8 |
dc.subject.otherIndex |
recombinant blood clotting factor 9 |
dc.subject.otherIndex |
adolescent |
dc.subject.otherIndex |
adult |
dc.subject.otherIndex |
arthropathy |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
bleeding |
dc.subject.otherIndex |
child |
dc.subject.otherIndex |
cost effectiveness analysis |
dc.subject.otherIndex |
disease severity |
dc.subject.otherIndex |
drug therapy |
dc.subject.otherIndex |
hemophilia |
dc.subject.otherIndex |
hospitalization |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
major clinical study |
dc.subject.otherIndex |
on demand therapy |
dc.subject.otherIndex |
orthopedic surgery |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
prophylaxis |
dc.subject.otherIndex |
quality of life |
dc.subject.otherIndex |
risk benefit analysis |
dc.subject.otherIndex |
risk reduction |
dc.subject.otherIndex |
vein puncture |
dc.subject.otherIndex |
viral contamination |
dc.subject.otherIndex |
Adolescent |
dc.subject.otherIndex |
Adult |
dc.subject.otherIndex |
Blood Coagulation Factors |
dc.subject.otherIndex |
Child |
dc.subject.otherIndex |
Child, Preschool |
dc.subject.otherIndex |
Cost-Benefit Analysis |
dc.subject.otherIndex |
Hemarthrosis |
dc.subject.otherIndex |
Hemophilia A |
dc.subject.otherIndex |
Hemorrhage |
dc.subject.otherIndex |
Hospitalization |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Middle Aged |
dc.subject.otherIndex |
Orthopedic Procedures |
dc.subject.otherIndex |
Premedication |
dc.subject.otherIndex |
Quality of Life |
dc.subject.otherKeywordPlus |
ORTHOPEDIC STATUS |
dc.subject.otherKeywordPlus |
ACCESS DEVICES |
dc.subject.otherKeywordPlus |
CHILDREN |
dc.subject.otherKeywordPlus |
INDIVIDUALS |
dc.subject.otherWOS |
Hematology |